-

AACR 2024: Brenus Pharma Unveils Promising and Robust Pre-clinical Efficacy Extrapolating Human Conditions with STC-1010

LYON, France--(BUSINESS WIRE)--Brenus Pharma unveils groundbreaking results during the American Association Cancer Research (AACR) Annual meeting 2024 – San Diego (April 5-10).

“Efficacy of the STC-10101 a new allogeneic cancer vaccine in different colorectal cancer models” | Abstract 5003 https://doi.org/10.1158/1538-7445.AM2024-5003

This communication confirms the ability of Brenus’ next gen immunotherapy, STC-1010, to fight against resistant colorectal tumors with excellent tolerability.

Additionally, multi-omics analysis of STC-1010 batches confirmed consistent quality and batch-to-batch reproducibility, through standardized and scalable production.

STC-1010 was tested in several models extrapolating human conditions (ex-vivo; in-ovo,) using PBMCs from different donors. Results showed a significant immune response activation coupled with a massive and robust tumor killing that has been consistent with our 3 latest STC1010 batches manufactured. Metastasis reduction has also been shown with in-ovo model.

Results show the potential of STC-1010 in clinical settings to treat patients with colorectal cancer causing 9.7 million death per year.

https://www.brenus-pharma.com/ | Follow us on LinkedIn

1 STC-1010 is a next-generation cancer immunotherapy produced by Allogeneic STC's proprietary Brenus platform. It’s specifically designed to combat colorectal cancer including MSS and MSI-H populations in its first line of treatment for the first indication. STC Platform mimics relapse conditions and allows eduction of patient’s immune system against resistant tumor.
2 Brenus Pharma, Lyon, France,
3 INSERM U1194 IRCM, Montpellier, France,
4 CNRS 6302, Dijon, France,
5 Anaquant, Lyon, France
6 Inovotion, La Tronche, France,
7 Explicyte, Bordeaux, France
8 Inserm 1231 CGFL, Dijon, France

Contacts

mbrun@brenus-pharma.com | (+33) 787768772

Industry:

Brenus Pharma

Release Versions
English
Hashtags
#AACR2024
#Biotech
#Cancervaccine
#Clinical
#Colorectalcancer
#Healthcare
#Immunotherapy

Contacts

mbrun@brenus-pharma.com | (+33) 787768772

Social Media Profiles
Follow Brenus Pharma
More News From Brenus Pharma

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients

LYON, France--(BUSINESS WIRE)--Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during do...

Brenus Pharma Expands Its Global Scientific Advisory Board With Us Immuno-Oncology Expert Prof. Olivera J. Finn

LYON, France & PITTSBURGH--(BUSINESS WIRE)--Brenus Pharma, a clinical-stage biotechnology company developing first-in-class in vivo immunotherapies for solid tumors, announced the appointment of Olivera J. Finn, Distinguished Professor at the University of Pittsburgh School of Medicine, to its Scientific Advisory Board (SAB). This strategic addition strengthens Brenus’ international SAB as the company advances its proprietary Stimulated Ghost Cell (SGC) platform and lead candidate STC-1010 towa...

Brenus Pharma Announces First Patients Dosed in its First-in-Human Trial Evaluating STC-1010, a Next-Generation Immunotherapy

LYON, France--(BUSINESS WIRE)--Brenus Pharma today announced that first patients have been successfully dosed in its first-in-human clinical trial evaluating STC-1010, the company’s lead in vivo immunotherapy candidate developed through its proprietary off-the-shelf platform. Three patients have already been enrolled in the study. The first completed eight weeks of treatment with no adverse events attributed to the investigational therapy. This trial targets patients with unresectable, locally...
Back to Newsroom